INTERNATIONAL ISSUES IN UROLOGIC ONCOLOGY

Conference Chair | Laurence Klotz, MD
Meeting Room: Room 5F Baekdu D

WELCOME & INTRODUCTIONS
7:15 Meet and Greet International Colleagues (coffee and refreshments served)
7:45 Framing of Theme | Laurence Klotz

ALL SCREENING TALKS 7 MINUTES FOLLOWED BY 3 MINUTE Q & A

7:50 SESSION ONE | PROSTATE CANCER SCREENING & PREVENTION | Co-Moderators: Ji Youl Lee & Laurence Klotz
7:55 Prostate Cancer Screening: European Perspective | Franz Recker, MD
8:05 Prostate Cancer Screening: American Perspective | Matthew Cooperberg, MD
8:15 Prostate Cancer Screening: Japanese Perspective | Shin Egawa, MD
8:25 Prostate Cancer Screening: Latin American Perspective | Arturo Mendoza-Valdés, MD
8:35 PSA Cutpoint Should be 1.5 | David Crawford, MD
8:45 FSH and Prostate Cancer | Jehonathan Pinhas, MD

9:00 DISCUSSION (10 mins)

9:10 SESSION TWO | PROSTATE CANCER MANAGEMENT OPTIONS | Co-Moderators: Yves Fradet & Sung Kyu Hong

CLINICAL CASE | Management of Grade Group 2 Prostate Cancer | (5 mins)

CARE & DEBATE | MANAGEMENT OF GRADE GROUP 2 PROSTATE CANCER
• Surveillance | Sung Kyu Hong, MD (10 mins)
• Focal Therapy | Rafael Sanchez-Salah, MD (10 mins)
• Radical Therapy | Neil Fleshner, MD (10 mins)

9:45 DISCUSSION (10 mins)

9:55 Can Ultrasound Imaging Replace MRI? | Peter Hammer, MD
10:07 Can MRI Replace Prostate Biopsy | Guillaume Ploussard, PhD
10:19 Integrating Imaging and Biomarkers in Prostate Cancer Decision Making | Derya Tilki, MD

10:29 DISCUSSION (10 mins)

10:40 SESSION THREE | KIDNEY CANCER | Co-Moderators: Alessandro Volpe & Ofer Yossepowitch
10:42 Challenges in Cystic Renal Tumours | Makarand Khochikar, MD
11:06 Where to Draw the Line Between Radical and Partial Nephrectomy? | Peter Mulders, MD
11:18 Adjutant Therapy in RCCPost Nephrectomy | Robert Flanigan, MD

11:30 DISCUSSION (5 mins)

11:35 WORKING LUNCH
Complimentary Meal to All Seated Participants Attending Session Four Working Lunch

12:00 SESSION FOUR | TOWN HALL

EMERGING DIAGNOSTIC BIOMARKERS IN PROSTATE CANCER | Moderator: Laurence Klotz
Introduction by Matthew Cooperberg: The Unmet Need for Liquid Biopsy in the Diagnostic Pathway
BENCH TO BEDSIDE: WHAT IS THE LATEST DATA ON EMERGING BIOMARKERS?
12:10 Urinary Micro RNAs and SNOs as a Prostate Cancer Biomarker Platform | mR Scientific
• Marlin Tenneswood, PhD
12:20 Emerging Biomarkers in Prostate Cancer | MDx Health | Jack Schalken, PhD
12:30 Radiogenomics | Robert Reiter, MD

12:40 PANELISTS | “BIOMARKERS IN PROSTATE CANCER”
Current Role of Molecular Biomarkers in the Management of Prostate Cancer. Which Ones and Why?
12:40 Panelist One | Shin Egawa
12:45 Panelist Two | Marc Dell’Era
12:50 Panelist Three | Robert Reiter
12:55 Panelist Four | Derya Tilki

1:00 OPEN DISCUSSION (30 mins)

1:30 SESSION FIVE | PROSTATE CANCER TREATMENT OPTIONS | Co-Moderators: Damien Bolton & John Davis
1:32 Improving the Outcome of Men on Active Surveillance | Marcel Dell’Era, MD
1:44 RP in Men Over Age 75: Is it folly? | Shomik Sengupta, MD
1:56 Advances in MR-US Fusion Guided | Art Rastinehad, MD

2:00 DISCUSSION (10 mins)

2:20 SESSION SIX | UROTHELIAL CANCER | Co-Moderators: Robert Siemens & Michael Leveridge
2:22 Liquid Biopsy for Bladder Cancer Prognosis | Peter Black, MD
2:34 Impact of Urinary Marker Testing in Bladder Cancer | Badrinath Konety, MD
2:46 Clinical Implications of Mutational Profiling of Invasive Bladder Cancer | Seth Lerner, MD
2:58 Should Variant Histology Change Management of Bladder Cancer? | Ashish Kamat, MD

3:10 DISCUSSION (10 mins)

3:20 SESSION SEVEN | ADVANCED PROSTATE CANCER | Moderator: Marco Bendhack
3:22 Medical Tourism in Urologic Oncology: Korean Perspective | Ji Youl Lee, MD
3:34 PSMA in the Management of Patients with Biochemical Failure | Shrawan Singh, MD
3:46 Chemotherapy and Radium for CRP - Role in the Era of ARTs | Peter Black, MD
3:58 How To Reduce Errors in Scientific Research | Laurence Klotz, MD

4:15 DISCUSSION (10 mins)

4:25 ADJOURN

www.wuof.org
Member Societies

Asian-Pacific Society of Urologic Oncology (APSUO)
Australian Urologic Oncology Section
British Association of Urologic Surgeons - Urologic Oncology Section (BAUS)
Canadian Urological Oncology Group (CUOG)
Chinese Urologic Oncology Group
European Society of Urologic Oncology
Georgian Association of Urological Oncology (GAOU)
German Society of Urologic Oncology
Indian Urological Society of Urologic Oncology
Israel Society of Urologic Oncology
Italian Society of Urologic Oncology
Japanese Society of Urologic Oncology
Korean Urological Oncology Society
Latin American Society of Urologic Oncology
Mexican Society of Uro-Oncology
Philippine Society of Urologic Oncology (PSUO)
Portuguese Ibero-Oncological Group
Spanish Society of Urologic Oncology
Turkish Urologic Oncology Society

FACULTY & PARTICIPANTS:

Australia

Professor Darren McInnes, MD, PhD, BA, MBBS, FRCS, FACS, FRACR, FRCPath
Director, Surgery, University of Melbourne
Member of the Chief Clinical Cancer and Wellness Centre
Austin Hospital, Melbourne

Shrikant Sanyal, MBBS, MS, MD, FRACS
General Surgeon, Invasive Urologic Surgeon
Professor of Surgery, Eastern Suburbs Clinical School, Monash University
Lakeside, Chirniner Street, Chirniner Avenue West, University of Melbourne

Peter Black, MD, FACS, FRCS, PhD
President, Family Cancer Foundation Inc., Melbourne
Director of Urology, St. Vincent's University Hospital, Melbourne

Neil Flintoff, MD, MHP, FRCS, FRACR
Professor of Urology
University of Melbourne, - Australia

Yuan Fang MD, CSGP-Urology
Professor of Urology
University of Sydney School of Medicine - Australia

Laurentine Klotz, MD, CM
Professor of Surgery, University of Toronto
Chairman, Department of Urology, Toronto General Hospital

Jie Youl, Lee, MD
Professor, Department of Urology
Seoul National University College of Medicine, Seoul, Korea

Sang Kyu Hong, MD, PhD
Professor, Department of Urology
Seoul National University College of Medicine, Seoul, Korea

Japan

Rafael Sanchez-Salas, MD
Attending Surgeon, Department of Urology, Mount Sinai Medical Center, New York, NY

Badrinath Konety, MD, FACS, MBA
Associate Cancer Center Director, RFHNH, Mumbai
Professor of Urologic Oncology
University of California, Los Angeles, CA

Ofer Yossepowitch
Professor of Urology, Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Mexico

Arturo Mendoza-Valdes, MD
UROOLOC
Hospital Médico Toluca, Toluca, Mexico

John W. Davis, MD
Professor of Urology
Department of Urology, University of California, Davis

Robert C. Flanigan, MD, FACS
Professor of Urology, Department of Urology
University of Alabama at Birmingham School of Medicine, Birmingham, AL

Phuthaphanh Phanouarn
Chairman, Department of Radiation Oncology, Lao National University Hospital, Vientiane, Lao PDR

The Netherlands

Alexandra Velaj, MD
Associate Professor of Urology, Department of Urology, University of Eastern Piedmont, Vercelli, Italy

Dr. Guillaume Provost, MD, FRCP, FFR
Chair, Urology, Hôpital Jules Vallée, Saint-Jean, France

Luis H. Martinez, MD
Chairman, Department of Urology, University of Western Cape, Cape Town, South Africa

Shin Egawa, MD
Professor, Head of the Department of Urology, Jichi Medical University, Tochigi, Japan

Jehonathan H. Pinthus, MD, PhD
Director of the Catholic Prostate Institute Research Institute, Philadelphia, PA

United States of America

Matthew R. Cooperberg, MD, MPH
Associate Professor of Clinical Research Affairs, Department of Urology, Emory University School of Medicine, Atlanta, GA

Seth P. Lerner, MD, FACS
Associate Professor of Urology, Department of Urology, Oregon Health & Science University, Portland, OR

Art R. Reinhart DO
Associate Professor of Urology, Radiation Oncology; Director of Focal Therapy and Interventional Urologic Oncology
St. Elizabeth's School of Medicine at Mt. Sinai.

Martin Tenniswood, PhD
Chief Scientific Officer
miRagen Therapeutics, LLC

Robert E. Reiter, MD, MBA
Surgical Oncologist in Private Practice, Radiation Oncology, Distinguished Member of The American College of Surgeons, Los Angeles, CA

John W. Davis, MD
Professor of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL

This meeting has been made possible by funding from our exhibitors and sponsors:

PLATINUM sponsor

GOLD sponsor

SANOFI GENZYME

SILVER sponsor

MDxHealth

With appreciation

INTERNATIONAL ISSUES IN UROLOGIC ONCOLOGY

FACULTY & PARTICIPANTS: